DRD2 and schizophrenia: Tateno et al reported the dopamine D2 receptor occupancy of blonanserin with fifteen patients with schizophrenia as part of an open‐label post‐marketing surveillance study (phase IV) in Japan.29 Three doses of 8, 16, and 24 mg/day were tested, and the optimal dose range was estimated to be 13‐22 mg/day.